Interested in Connecting? Please contact: Michael Fossel President firstname.lastname@example.org
Message the company or request a 1:1 meeting here.
Telocyte uses a novel approach that addresses the fundamental alterations in gene expression that underlie age-related human dementias, including Alzheimer’s disease. Our technique resets age-related behavioral decline, using telomerase, an enzyme that resets gene expression to that of normal young cells. The intervention is uniformly effective in animal trials and is entirely applicable to human patients. The rationale of our approach and the effective point of intervention are explained in the paper “A unified model of dementias and age-related neurodegeneration” (Fossel. Alzheimer’s & Dementia, 2020). The article generated more than 600 reprint requests in the first two weeks.
Our scientific advisory board and our clinical advisory board are remarkable for the expertise of the members, who have global reputations in the Alzheimer’s community and who run major Alzheimer’s centers, animal testing laboratories, gene therapy institutes, and global firms that consult on the design and statistical analysis of Alzheimer’s trials. Telocyte seeks a #30 million Series A equity investment, to complete our Phase 1 and Phase 2 Alzheimer’s trials.